{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:12:03Z","timestamp":1649117523661},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T00:00:00Z","timestamp":1295136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s00115-010-3091-8","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T12:41:00Z","timestamp":1295008860000},"page":"475-480","source":"Crossref","is-referenced-by-count":4,"title":["Progressive multifokale Leukenzephalopathie unter Natalizumab"],"prefix":"10.1007","volume":"82","author":[{"given":"C.","family":"Warnke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,16]]},"reference":[{"key":"3091_CR1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"3091_CR2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911\u2013923","journal-title":"N Engl J Med"},{"key":"3091_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"3091_CR4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911\u2013923","journal-title":"N Engl J Med"},{"key":"3091_CR5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"3091_CR6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924\u2013933","journal-title":"N Engl J Med"},{"key":"3091_CR7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, DeLuca A et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438\u2013446","journal-title":"Lancet Neurol"},{"key":"3091_CR8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00115-009-2701-9","volume":"80","author":"Hartung","year":"2009","unstructured":"Hartung HP, Warnke C, Hohlfeld R, Kieseier BC (2009) Progressive multifokale Leukencephalopathie. Unerw\u00fcnsche Nebenwirkung einer Immuntherappie. Nervenarzt 80:1143\u20131153","journal-title":"Nervenarzt"},{"key":"3091_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","volume":"6","author":"Kappos","year":"2007","unstructured":"Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431\u2013441","journal-title":"Lancet Neurol"},{"key":"3091_CR10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","volume":"361","author":"Wenning","year":"2009","unstructured":"Wenning W, Haghikia A, Laubenberger J et al (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075\u20131080","journal-title":"N Engl J Med"},{"key":"3091_CR11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1474-4422(08)70281-3","volume":"8","author":"Hartung","year":"2009","unstructured":"Hartung HP (2009) New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8:28\u201331","journal-title":"Lancet Neurol"},{"key":"3091_CR12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","volume":"361","author":"Lind\u00e5","year":"2009","unstructured":"Lind\u00e5 H, Heijne A von, Major EO et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081\u20131087","journal-title":"N Engl J Med"},{"key":"3091_CR13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00415-008-0061-1","volume":"255","author":"Wiendl","year":"2008","unstructured":"Wiendl H, Toyka KV, Rieckmann P et al (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255:1449\u20131463","journal-title":"J Neurol"},{"key":"3091_CR14","unstructured":"Imperiale M, Major EO (2007) Polyomaviruses. Fields Virology. 5. Aufl. Lippincott Williams & Wilkins, Philadelphia, S 2263\u20132298"},{"key":"3091_CR15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"Egli","year":"2009","unstructured":"Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837\u2013846","journal-title":"J Infect Dis"},{"key":"3091_CR16","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","volume":"5","author":"Kean","year":"2009","unstructured":"Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363","journal-title":"PLoS Pathog"},{"key":"3091_CR17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1099\/vir.0.18842-0","volume":"84","author":"Stolt","year":"2003","unstructured":"Stolt A, Sasnauskas K, Koskela P et al (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84:1499\u20131504","journal-title":"J Gen Virol"},{"key":"3091_CR18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","volume":"71","author":"Knowles","year":"2003","unstructured":"Knowles WA, Pipkin P, Andrews N et al (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115\u2013123","journal-title":"J Med Virol"},{"key":"3091_CR19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/gut.2007.145698","volume":"57","author":"Verbeeck","year":"2008","unstructured":"Verbeeck J, Van Assche G, Ryding J et al (2008) JC viral loads in patients with Crohn\u2019s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57:1393\u20131397","journal-title":"Gut"},{"key":"3091_CR20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jmv.21710","volume":"82","author":"Matos","year":"2010","unstructured":"Matos A, Duque V, Beato S et al (2010) Characterization of JC human polyomavirus infection in a portuguese population. J Med Virol 82:494\u2013504","journal-title":"J Med Virol"},{"key":"3091_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/0-387-32957-9_2","volume":"577","author":"Knowles","year":"2006","unstructured":"Knowles WA (2006) Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 577:19\u201345","journal-title":"Adv Exp Med Biol"},{"key":"3091_CR22","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1128\/JVI.72.12.9918-9923.1998","volume":"72","author":"Monaco","year":"1998","unstructured":"Monaco MC, Jensen PN, Hou J et al (1998) Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 72:9918\u20139923","journal-title":"J Virol"},{"key":"3091_CR23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1086\/374739","volume":"187","author":"Ling","year":"2003","unstructured":"Ling PD, Lednicky JA, Keitel WA et al (2003) The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 187:1571\u20131580","journal-title":"J Infect Dis"},{"key":"3091_CR24","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/JCM.35.5.1255-1257.1997","volume":"35","author":"Kitamura","year":"1997","unstructured":"Kitamura T, Sugimoto C, Kato A et al (1997) Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains. J Clin Microbiol 35:1255\u20131257","journal-title":"J Clin Microbiol"},{"key":"3091_CR25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","volume":"361","author":"Chen","year":"2009","unstructured":"Chen Y, Bord E, Tompkins T et al (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067\u20131074","journal-title":"N Engl J Med"},{"key":"3091_CR26","first-page":"2489","volume":"361","author":"Warnke","year":"2009","unstructured":"Warnke C, Adams O, Kieseier BC (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:2489; author reply 2489\u20132490","journal-title":"N Engl J Med"},{"key":"3091_CR27","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJMp0906248","volume":"361","author":"Major","year":"2009","unstructured":"Major EO (2009) Reemergence of PML in natalizumab-treated patients\u2013new cases, same concerns. N Engl J Med 361:1041\u20131043","journal-title":"N Engl J Med"},{"key":"3091_CR28","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMc0909622","volume":"361","author":"Gorelik","year":"2009","unstructured":"Gorelik L, Goelz S, Sandrock AW (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:2487\u20132488; author reply 2489\u20132490","journal-title":"N Engl J Med"},{"key":"3091_CR29","doi-asserted-by":"crossref","unstructured":"Rudick RA, O\u2018Connor PW, Polman CH et al (2010) Assessment of JC virus in blood and urine from natalizumab-treated patients. Ann Neurol (in press)","DOI":"10.1002\/ana.22107"},{"key":"3091_CR30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(10)70006-5","volume":"9","author":"Jilek","year":"2010","unstructured":"Jilek S, Jaqui\u00e9ry E, Hirsch HH et al (2010) Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 9:264\u2013272","journal-title":"Lancet Neurol"},{"key":"3091_CR31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1474-4422(10)70124-1","volume":"9","author":"Tan","year":"2010","unstructured":"Tan CS, Chen Y, Viscidi RP et al (2010) Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol 9:565\u2013566; author reply 566\u2013567","journal-title":"Lancet Neurol"},{"key":"3091_CR32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1474-4422(10)70025-9","volume":"9","author":"Ransohoff","year":"2010","unstructured":"Ransohoff RM (2010) PML risk and natalizumab: more questions than answers. Lancet Neurol 9:231\u2013233","journal-title":"Lancet Neurol"},{"key":"3091_CR33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0029-1220429","volume":"36","author":"Gold","year":"2009","unstructured":"Gold R, Hartung HP, Hohlfeld R et al (2009) Therapie der Multiplen Sklerose mit monoklonalen Antik\u00f6rpern. Akt Neurol 36:334\u2013344","journal-title":"Akt Neurol"},{"key":"3091_CR34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.21443","volume":"64","author":"Perez-Liz","year":"2008","unstructured":"Perez-Liz G, Del Valle L, Gentilella A et al (2008) Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 64:379\u2013387","journal-title":"Ann Neurol"},{"key":"3091_CR35","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","volume":"63","author":"St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Marra CM, Bar-Or A et al (2006) Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63:1383\u20131387","journal-title":"Arch Neurol"},{"key":"3091_CR36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","volume":"59","author":"St\u00fcve","year":"2006","unstructured":"St\u00fcve O, Marra CM, Jerome KR et al (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743\u2013747","journal-title":"Ann Neurol"},{"key":"3091_CR37","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00415-009-5444-4","volume":"257","author":"Sadiq","year":"2010","unstructured":"Sadiq SA, Puccio LM, Brydon EWA (2010) JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol 257:954\u2013958","journal-title":"J Neurol"},{"key":"3091_CR38","doi-asserted-by":"crossref","unstructured":"Gorelik L, Lerner M, Bixler S et al (2010) Anti-JCV antibodies: implications for PML-risk stratification. Ann Neurol (in press)","DOI":"10.1002\/ana.22128"},{"key":"3091_CR39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","volume":"6","author":"Kappos","year":"2007","unstructured":"Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431\u2013441","journal-title":"Lancet Neurol"},{"key":"3091_CR40","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01071083?term=natalizumab&rank=13"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-3091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-010-3091-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-3091-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T16:35:39Z","timestamp":1592238939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-010-3091-8"}},"subtitle":["Erste M\u00f6glichkeiten einer Risikostratifizierung?"],"short-title":[],"issued":{"date-parts":[[2011,1,16]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["3091"],"URL":"https:\/\/doi.org\/10.1007\/s00115-010-3091-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,16]]}}}